article thumbnail

‘Proactive’ vaccine can protect against unknown future coronaviruses

Drug Discovery World

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. By training the immune system to attack these regions, it gives protection against other coronaviruses not represented in the vaccine.

Vaccine 130
article thumbnail

One coronavirus vaccine may protect against other coronaviruse

The Pharma Data

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

Vaccine 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PFIZER ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER FRANK D’AMELIO

The Pharma Data

Mike McDermott has been with Pfizer for 18 times having started with the Company in 2003 as head of also Wyeth’s Biotech Manufacturing Operations at its Pearl River, New York point. As a result of his sweats, Pfizer expects to achieve the thing of producing 3 billion boluses of COVID-19 vaccines in 2021 and 4 billion boluses in 2022.

Vaccine 52
article thumbnail

Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health

The Pharma Data

Michael Nally has served as chief marketing officer for Human Health since January 2019, following three years leading Merck’s global vaccines business. Nally has been at Merck since 2003 and served in a number of roles with increasing responsibilities including the managing director of the company’s U.K.,

article thumbnail

Enlisting Monoclonal Antibodies in the Fight Against COVID-19

NIH Director's Blog: Drug Development

This structural information helps to clarify the precise biochemistry of the complex interaction between SARS-CoV-2 and the antibody, providing a much-needed guide for the rational design of targeted drugs and vaccines. In the U.S. Stay tuned for more information about these potentially significant advances in the next few months.

Virus 52
article thumbnail

Finding New Ways to Fight Coronavirus … From Studying Bats

NIH Director's Blog: Drug Development

He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. He’s also a member of the international research team that identified a human antibody, called S309, from a person who’d been infected with SARS in 2003.

Virus 52
article thumbnail

China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis

The Pharma Data

Active LN was confirmed by renal biopsy during screening visit using the 2003 International Society of Nephrology/Renal Pathology Society criteria within the past six months, and clinically active kidney disease requiring induction therapy. [i]. About lupus.